One week after the transfer, it was possible to detect T cells producing IFN-γ in response to tumor antigen in the blood of half of the patients (6 of 12), referred to as a type-1 response, showing that these transferred T cells could persist for a while and target cancer cells. This evidence concerns the gene IFNG and cancer.